2022
Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure
Qu R, Kluger Y, Yang J, Zhao J, Hafler D, Krause D, Bersenev A, Bosenberg M, Hurwitz M, Lucca L, Kluger H. Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure. Molecular Cancer 2022, 21: 219. PMID: 36514045, PMCID: PMC9749221, DOI: 10.1186/s12943-022-01688-5.Peer-Reviewed Original ResearchConceptsAdoptive cell therapySingle-cell analysisDepth single-cell analysisSingle-cell RNAACT productsDisease progressionT-cell receptor sequencingCell therapyFamily genesFeatures of exhaustionMultiple tumor typesCell expansionGenesNew clonotypesTIL preparationsClonal cell expansionCytokine therapyTreatment failureSerial bloodClonesEffector functionsSerial samplesTumor typesCellular therapyTherapy
2019
CHAPTER 2 Genetics of Multiple Sclerosis
Abulaban A, Hafler D, Longbrake E. CHAPTER 2 Genetics of Multiple Sclerosis. 2019, 33-54. DOI: 10.1039/9781788016070-00033.ChaptersMultiple sclerosisCentral nervous systemImmune cell infiltratesComplex autoimmune diseaseEnvironmental risk factorsExtensive CNS demyelinationMS therapyAxonal damageCell infiltrateCNS demyelinationAutoimmune diseasesRisk factorsGenetic predispositionNervous systemDisease severityDiseaseSclerosisComplex genetic diseasesChapter 2 GeneticsGenetic diseasesDemyelinationInfiltratesAutoimmunityPathogenesisTherapy
2018
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization
Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers In Immunology 2018, 8: 1844. PMID: 29379498, PMCID: PMC5775516, DOI: 10.3389/fimmu.2017.01844.Peer-Reviewed Original ResearchAntigen-presenting cellsRegulatory cellsTolerogenic antigen-presenting cellsT regulatory (Treg) cellsClinical applicationPosttransplant complicationsTreg preparationsAllergic diseasesClinical trialsTregsEfficacious treatmentTreg productsCellular therapyStandardized reportingMedicinal productsDifferent preparationsCellsInvestigatorsCD4ComplicationsTherapyDiseaseTrials
2015
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nature Reviews Neurology 2015, 11: 504-514. PMID: 26260659, PMCID: PMC4782584, DOI: 10.1038/nrneurol.2015.139.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsGlioblastoma patientsMultiple immunosuppressive mechanismsMedian overall survivalImmune checkpoint modulatorsBlood-brain barrierTreatment of glioblastomaOverall survivalImmunosuppressive mechanismsAdvanced tumorsClinical benefitImmunotherapeutic agentsConventional therapyCheckpoint modulatorsLung cancerImmune systemPatientsCancerInhibitorsCurrent understandingImmunotherapyPrognosisLymphocytesTherapy
2014
Chapter 52 Multiple Sclerosis
Hernandez A, O’Connor K, Hafler D. Chapter 52 Multiple Sclerosis. 2014, 735-756. DOI: 10.1016/b978-0-12-384929-8.00052-6.ChaptersMultiple sclerosisT cellsCell subsetsInflammatory autoimmune diseaseRegulatory T cellsT cell subsetsCNS white matterB cell subsetsImmune dysregulationTh1 subsetAutoimmune diseasesHumoral responseDisease evolutionInfectious agentsGenetic susceptibility lociProgressive neurodegenerationWhite matterCurrent diseaseGenetic riskDiseasePotential roleSclerosisSusceptible hostsTherapyPutative role
2012
Erratum: Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonb therapy in multiple sclerosis
Vosslamber S, van der Voort L, van den Elskamp I, Heijmans R, Aubin C, Uitdehaag B, Crusius J, van der Pouw Kraan T, Comabella M, Montalban X, Hafler D, De Jager P, Killestein J, Polman C, Verweij C. Erratum: Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonb therapy in multiple sclerosis. Genes & Immunity 2012, 13: 443-443. DOI: 10.1038/gene.2012.18.Peer-Reviewed Original Research
2008
The developing mosaic of autoimmune disease risk
Maier LM, Hafler DA. The developing mosaic of autoimmune disease risk. Nature Genetics 2008, 40: 131-132. PMID: 18227869, DOI: 10.1038/ng0208-131.Peer-Reviewed Original Research
2005
Multiple sclerosis
Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher‐Allan C. Multiple sclerosis. Immunological Reviews 2005, 204: 208-231. PMID: 15790361, DOI: 10.1111/j.0105-2896.2005.00240.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMultiple sclerosisT cellsB cellsImmunopathology of MSCentral nervous system white matterNervous system white matterRegulatory T cellsHallmark of inflammationImmunosuppressive therapyAutoimmune processImmunomodulatory therapeuticsAnimal modelsMS researchWhite matterDisease pathologyClonal expansionDiseaseMajor histocompatibility complex (MHC) genesMolecular pathologyRNA expressionSclerosisInflammationTherapyPathologyComplex genetic diseases
2004
Multiple sclerosis
Hafler DA. Multiple sclerosis. Journal Of Clinical Investigation 2004, 113: 788-794. PMID: 15067307, PMCID: PMC362131, DOI: 10.1172/jci21357.Peer-Reviewed Original ResearchConceptsMultiple sclerosisT cellsAutoreactive T cellsCNS white matterHallmark of inflammationB cellsWhite matterClonal expansionMolecular pathologyRNA expressionDiseaseSclerosisInflammationComplex genetic diseasesHuman diseasesCellsAntibody productsGenetic diseasesHigh-throughput examinationTherapyPathology
2000
Antigen-specific therapy for autoimmune disease
Harrison L, Hafler D. Antigen-specific therapy for autoimmune disease. Current Opinion In Immunology 2000, 12: 704-711. PMID: 11102776, DOI: 10.1016/s0952-7915(00)00166-7.Peer-Reviewed Original Research
1999
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol M, Olek M, John Orav E, Stazzone L, Hafler D, Khoury S, Dawson D, Weiner H. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: Response to therapy is linked to the duration of progressive disease. Multiple Sclerosis Journal 1999, 5: 403-409. DOI: 10.1191/135245899678846492.Peer-Reviewed Original Research
1996
Antigen-specific therapies for the treatment of autoimmune diseases
Hafler D, Weiner H. Antigen-specific therapies for the treatment of autoimmune diseases. 1996, 61-76. DOI: 10.1007/978-3-642-61191-9_6.Peer-Reviewed Original ResearchAntigen-specific therapyInfectious agentsMajor histocompatibility complexAutoimmune disordersAutoimmune diseasesT cellsLocal antigen-presenting cellsOrgan-specific autoimmune diseasesHuman autoimmune disordersAntigen-presenting cellsOrgan-specific proteinsRange of antigensAutoimmune processAutoimmune cascadeHistocompatibility complexDisordersTherapyDiseasePrimary targetCellsVirusOrgansAgentsSuperantigensEtiology
1995
Therapy for Multiple Sclerosis
Weiner H, Hohol M, Khoury S, Dawson D, Hafler D. Therapy for Multiple Sclerosis. Neurologic Clinics 1995, 13: 173-196. PMID: 7739502, DOI: 10.1016/s0733-8619(18)30066-5.Peer-Reviewed Original ResearchConceptsMultiple sclerosisCell-mediated autoimmune diseaseAccumulation of disabilityMultiple sclerosis patientsSymptomatic therapySclerosis patientsAutoimmune responseCentral nervous system myelinAutoimmune diseasesNonspecific modulationImmune systemSclerosisSystem myelinTherapyImmunotherapyPatientsDiseaseMyelin
1993
The development of antigen specific therapies for autoimmune diseases; investigations in multiple sclerosis as a paradigm for rheumatoid arthritis.
Hafler DA, Zhang JW, LaSalle J, Donnelly C, Weiner HL, Wucherpfeffnig K. The development of antigen specific therapies for autoimmune diseases; investigations in multiple sclerosis as a paradigm for rheumatoid arthritis. Clinical And Experimental Rheumatology 1993, 11 Suppl 8: s39-40. PMID: 7686832.Peer-Reviewed Original Research
1992
Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction
Krumholz H, Pasternak R, Weinstein M, Friesinger G, Ridker P, Tosteson A, Goldman L. Cost Effectiveness of Thrombolytic Therapy with Streptokinase in Elderly Patients with Suspected Acute Myocardial Infarction. New England Journal Of Medicine 1992, 327: 7-13. PMID: 1598117, DOI: 10.1056/nejm199207023270102.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyRisk of deathMyocardial infarctionElderly patientsPatients 75 yearsST-segment elevationOnset of symptomsUse of streptokinaseOne-way sensitivity analysesDecision analytic modelYears of lifeCost-effective treatmentRelative reductionHospital deathStreptokinase therapyOlder patientsClinical circumstancesThrombolytic agentsInfarctionPatientsCost effectivenessTherapyLack of consensusStreptokinase
1991
The Potential of Restricted T Cell Recognition of Myelin Basic Protein Epitopes in the Therapy of Multiple Sclerosis
HAFLER D, MATSUI M, WUCHERPFENNIG K, OTA K, WEINER H. The Potential of Restricted T Cell Recognition of Myelin Basic Protein Epitopes in the Therapy of Multiple Sclerosis. Annals Of The New York Academy Of Sciences 1991, 636: 251-265. PMID: 1724362, DOI: 10.1111/j.1749-6632.1991.tb33456.x.Peer-Reviewed Original Research
1988
Cumulative Experience with High‐Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis
CARTER J, DAWSON D, HAFLER D, FALLIS R, STAZZONE L, ORAV J, WEINER H. Cumulative Experience with High‐Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis. Annals Of The New York Academy Of Sciences 1988, 540: 535-536. PMID: 2849902, DOI: 10.1111/j.1749-6632.1988.tb27163.x.Peer-Reviewed Original Research
1987
Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
Dawson DM, Carter JL, Hafler DA, Weiner HL. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. Nuova Rivista Di Neurologia 1987, 57: 88-91. PMID: 3039645.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisMonoclonal antibody therapyMultiple sclerosisAntibody therapyChronic progressive multiple sclerosisHigh-dose intravenous cyclophosphamideMultiple sclerosis patientsForm of treatmentLong-term controlIntravenous cyclophosphamideSclerosis patientsClinical resultsSerious toxicityImmune parametersPilot trialCyclophosphamideNervous systemSclerosisTerm controlsPatientsMonoclonal antibodiesACTHOnly small numbersTherapyAdverse effects